

DRIZALMA SPRINKLE (duloxetine delayed-release, oral)

Diagnosis Considered for Coverage:

- Major Depression Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Diabetic Peripheral Neuropathic Pain (DPNP)
- Chronic musculoskeletal pain (e.g. chronic low back pain and chronic pain due to osteoarthritis)

Coverage Criteria:

For all diagnoses above, approve if:

- Dose does not exceed 120 mg per day, and
- Patient is unable to take generic duloxetine delayed-release capsule (Cymbalta) due to an intrinsic swallowing defect.

Coverage Duration: Length of benefit

Effective: 12/04/2019GF